NCT01910038View on ClinicalTrials.gov

Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

June 13, 2016

Conditions

Giant Cell Arteritis

Interventions

DRUG

corticoids+ tocilizumab 8mg/Kg/4 weeks

Trial Locations (8)

14033

CHU de Caen - Hôpital Côte de Nacre, Caen

21079

CHU de Dijon, Dijon

57045

Hôpitaux privés de Metz - Site Sainte Blandine, Metz

69437

Hôpital Edouard HERRIOT, Lyon

75014

Institut Mutualiste Montsouris, Paris

75651

Hôpital La Pitié-Salpêtrière, Paris

75679

Hôpital COCHIN, Paris

87042

Chu Dupuytren, Limoges

All Listed Sponsors

lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT01910038 - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. | Biotech Hunter | Biotech Hunter